Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 152 for:    HTT

Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03912974
Recruitment Status : Not yet recruiting
First Posted : April 12, 2019
Last Update Posted : June 4, 2019
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT receptors, e.g. the 5-HT2A receptor. The aim of the study is to investigate the effects of psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects as well as effects on gene expression will be assessed.

Condition or disease Intervention/treatment Phase
Healthy Drug: Escitalopram Drug: Placebo oral capsule Phase 1

Detailed Description:

Psilocybin (the active substance in "magic mushrooms") is a classic serotonergic hallucinogen acting on the serotonin 5-HT2A receptor. Psilocybin is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression. SSRIs like escitalopram are currently among the first-line treatments of this disorder. Escitalopram acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to psilocybin.

Participants will be treated with escitalopram (10 mg in the 1st and 20 mg in the 2nd week) or placebo for 14 days. Pretreatment is followed the first study day. A single dose of psilocybin (25 mg) will be administered. Primary study endpoint are the subjective effects on consciousness (measured by the 5D-ASC total score). Secondary study endpoints include additional psychological measurements, plasma concentrations of psilocybin and escitalopram, hydroxytryptamine receptor (HTR) gene expression, as well as some safety measures (autonomic effects, ECG). The washout between the first study day and the second pretreatment will be at least 2 days. In the second pretreatment period, participants will be treated with placebo or escitalopram (cross-over) for another 14 days. This is followed by the second study day and administration of psilocybin (25 mg).

Based on a power analysis the sample size is 24 participants (12 female and 12 male).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: 2-period cross-over, randomized, double-blinded (escitalopram vs. placebo)study
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Pretreatment condition is double-blinded (escitalopram 10 mg x 7 days, then 20 mg orally x 7 days vs. placebo (mannitol) orally x 14 days) On each of the 2 study days, participants will receive psilocybin 25 mg orally (no placebo control on the study days)
Primary Purpose: Basic Science
Official Title: Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Pretreatment with escitalopram
Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
Drug: Escitalopram
see 'arm description'

Placebo Comparator: Pretreatment with placebo oral capsule
Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
Drug: Placebo oral capsule
see 'arm description'




Primary Outcome Measures :
  1. 5 dimensions of altered state of consciousness (5D-ASC) profile total score [ Time Frame: 20 Months ]
    Visual analog scale consisting of 94 items. Constructed of five scales and allows assessing mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. Scales will be presented as 100 mm long horizontal lines marked with vertical lines by the participant.


Secondary Outcome Measures :
  1. Visual Analog Scales (VAS) [ Time Frame: 20 Months ]
    VAS will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with "not at all" on the left and "extremely" on the right. The following VAS will be used: "any effect", "good effect", "bad effect","liking", "high", "happy", "fear", "stimulated", "feeling close to others", "concentration", "thinking", "open", "trust", "want to be with other people", "loss of sense of time", and "the boundaries between myself and my surroundings seemed to blur". Subjects will mark the scale with vertical lines.

  2. Adjective mood rating scale (AMRS) [ Time Frame: 20 Months ]
    The adjective mood rating scale (AMRS or EWL60S) is a 60-item Likert scale that allows repeated assessment of mood in 6 dimensions: activation, inactivation, well-being, anxiety/depressed mood, extroversion and introversion, and emotional excitability.The AMRS consists of subscales measuring "activation", "positive mood", "extroversion", "introversion", "inactivation", and "emotional excitability.

  3. States of consciousness questionnaire (SCQ) [ Time Frame: 20 Months ]
    This 100-item questionnaire is rated on a six-point scale. Forty-three items embedded into this questionnaire comprise the Mystical Experience Questionnaire (MEQ). which is sensitive to the effects of psilocybin. The 43 items provide scale scores for each of seven domains of mystical experiences: internal unity (pure awareness, a merging with ultimate reality), external unity (unity of all things, all things are alive, all is one), sense of sacredness (reverence, sacred), noetic quality (encounter with ultimate reality, more real than everyday reality), transcendence of time and space, deeply felt positive mood (joy, peace, love), paradoxicality/ineffability (claim of difficulty in describing the experience in words). We will also derived the four scale scores of the newly validated revised 30-item MEQ: mystical, positive mood, transcendence of time and space, and ineffability.

  4. Mysticism scale (MS) [ Time Frame: 20 Months ]
    The MS is a 32-item questionnaire that was developed to assess primary mystical experiences. The items are rated on a 9-point Likert scale. The scale consists of 16 positively worded statements and 16 negatively worded statements.

  5. Eppendorf Schizophrenia Inventory (ESI) [ Time Frame: 20 Months ]
    The ESI yields four schizophrenia-specific dimensions: attention and speech impairment (AS), ideas of reference (IR), auditory uncertainty (AU), and deviant perception (DP).

  6. Blood pressure [ Time Frame: 20 Months ]
    Repeatedly measured using blood pressure / pulse apparatus (mmHg scale)

  7. Heart rate [ Time Frame: 20 Months ]
    Repeatedly measured using blood pressure / pulse apparatus (beats per minute scale)

  8. Body temperature [ Time Frame: 20 Months ]
    Repeatedly measured using ear thermometer (degree Celsius scale)

  9. Pupil diameter [ Time Frame: 20 Months ]
    Repeatedly measured using pupil distance meter (millimeter scale)

  10. Plasma concentrations of escitalopram [ Time Frame: 20 Months ]
    Escitalopram plasma concentrations will be measured repeatedly over time using LC-MS/MS techniques (nanogram per milliliter scale)

  11. Plasma concentrations of psilocin [ Time Frame: 20 Months ]
    Escitalopram plasma concentrations will be measured repeatedly over time using LC-MS/MS techniques (nanogram per milliliter scale)

  12. HTR gene expression [ Time Frame: 20 Months ]
    Messenger ribonucleic acid (mRNA) expression levels in whole blood as a peripheral marker of spiny neuronal gene (CNS) expression will be used to measure expression of HTR genes as well as expression of the SERT gene.

  13. Changes in the electrocardiogram (ECG) [ Time Frame: 20 Months ]
    12-lead electrocardiogram will be measured twice on the study days (baseline and at peak drug effect) as well as on the screening exam to examine possible drug-induced changes in the ECG as well as a safety measure (millisecond scale).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age between 25 and 65 years.
  2. Understanding of the German language.
  3. Understanding the procedures and the risks that are associated with the study.
  4. Participants must be willing to adhere to the protocol and sign the consent form.
  5. Participants must be willing to refrain from taking illicit psychoactive substances during the study.
  6. Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day.
  7. Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after substance administration.
  8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session.
  9. Women of childbearing potential must be willing to use double-barrier birth control.

Exclusion Criteria:

  1. Chronic or acute medical condition, including a history of seizures.
  2. Current or previous major psychiatric disorder (e.g. psychotic disorders, mania / hypomania, anxiety disorders, and substance abuse).
  3. Psychotic disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or lesions of the brain.
  4. Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months.
  5. History of an angle closure glaucoma.
  6. Pregnant or nursing women.
  7. Participation in another clinical trial (currently or within the last 30 days).
  8. Use of medications that may interfere with the effects of the study medications (any psychiatric medications and any medication with known pharmacokinetic or pharmacodynamic interactions with escitalopram).
  9. A corrected QT time (QTc), calculated by Bazett's formula, of over 450 milliseconds in males and over 470 milliseconds in females.
  10. Tobacco smoking (>10 cigarettes/day).
  11. Consumption of alcoholic drinks (>10 drinks / week).
  12. Bodyweight < 45 kg.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03912974


Contacts
Layout table for location contacts
Contact: Matthias E Liechti, MD, MAS 613286868 ext +41 matthias.liechti@usb.ch
Contact: Tim Buehler, MD 613286847 ext +41 tim.buehler@usb.ch

Locations
Layout table for location information
Switzerland
University Hospital Basel, Clinical Trial Unit Not yet recruiting
Basel, BS, Switzerland, 4056
Contact: Matthias E Liechti, MD, MAS         
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Matthias E Liechti, MD, MAS University Hospital, Basel, Switzerland

Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT03912974     History of Changes
Other Study ID Numbers: BASEC 2019-00223
First Posted: April 12, 2019    Key Record Dates
Last Update Posted: June 4, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Citalopram
Dexetimide
Psilocybin
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Hallucinogens